Kite Pharma Competitors and Similar CompaniesClear all
G1 Therapeutics's competitors and similar companies include Achilles Therapeutics, Amgen, Juno Therapeutics and Adaptive Biotechnologies.
 G1 Therapeutics G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. |  Achilles Therapeutics Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer. |  Amgen Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. |  Juno Therapeutics Juno Therapeutics is a clinical-stage company, which develops immunotherapies for the treatment of cancer. |  Adaptive Biotechnologies Adaptive Biotechnologies (formerly known as Adaptive TCR) is a company that develops diagnostics and therapeutic tools based on the immune response to disease. | |
Founding Date | Founding Date 2008 | Founding Date 2016 | Founding Date 1980 | Founding Date 2013 | Founding Date 2009 |
Type | Type Public | Type Private | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Durham, US HQ | Locations London, GB HQ Stevenage, GB | Locations Thousand Oaks, US HQ Hydra, DZ Vicente López, AR Sydney, AU Wien, AT Diegem, BE Santo Amaro, BR see more | Locations Seattle, US HQ Göttingen, DE Göttingen, DE München, DE München, DE Bothell, US Brisbane, US | Locations Seattle, US HQ New York, US South San Francisco, US |
Employees | Employees 17015% increase | Employees 695% decrease | Employees 25,200 | Employees 1091% decrease | Employees 70910% decrease |
Valuation ($) | Valuation ($) 377.2 m | Valuation ($) N/A | Valuation ($) 170.4 b | Valuation ($) N/A | Valuation ($) 694.6 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $82.5m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $36.8b (FY, 2025) | Revenue (est.) $111.9m (FY, 2017) | Revenue (est.) $277m (FY, 2025) |
Cost of goods | Cost of goods $7.2m (FY, 2023) | Cost of goods N/A | Cost of goods $12b (FY, 2025) | Cost of goods N/A | Cost of goods $71.4m (FY, 2025) |
Gross profit | Gross profit $75.3m (FY, 2023) | Gross profit N/A | Gross profit $24.7b (FY, 2025) | Gross profit N/A | Gross profit $205.6m (FY, 2025) |
Net income | Net income ($48m) (FY, 2023) | Net income ($69.7m) (FY, 2023) | Net income $7.7b (FY, 2025) | Net income ($437.1m) (FY, 2017) | Net income ($59.5m) (FY, 2025) |
Operating ⚠ | |||||
Patents (US) | Patents (US) 40 (FY, 2020) | Patents (US) N/A | Patents (US) 31 (FY, 2020) | Patents (US) 72 (FY, 2016) | Patents (US) N/A |
Funding | |||||
Total funding raised | Total funding raised $ 289.6m | Total funding raised $ 138.1m | Total funding raised N/A | Total funding raised $ 310m | Total funding raised $ 525m |
For sources of this data, please see the company profile
View Company Profiles
Achilles Therapeutics
HQ
London, GB
Employees
69↓ 5% decrease
Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer.
View companyAmgen
HQ
Thousand Oaks, US
Employees
25,200
Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics.
View companyJuno Therapeutics
HQ
Seattle, US
Juno Therapeutics is a clinical-stage company, which develops immunotherapies for the treatment of cancer.
View companyAdaptive Biotechnologies
HQ
Seattle, US
Employees
709↓ 10% decrease
Adaptive Biotechnologies (formerly known as Adaptive TCR) is a company that develops diagnostics and therapeutic tools based on the immune response to disease.
View company